The aspirin story – from willow to wonder drug

British Journal of Haematology

Volumn 177, Issue 5, 2017, Pages 674-683

  Desborough, Michael J R ^a,b   Keeling, David M ^c  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c CHURCHILL HOSPITAL   (United Kingdom)

Author keywords

acetylsalicylic acid; antiplatelet agent; aspirin; history; willow

Indexed keywords

ACETYLSALICYLIC ACID; ARACHIDONIC ACID; DIAMORPHINE; INDOMETACIN; SALICIN; STREPTOKINASE; ANTIPYRETIC AGENT; ANTITHROMBOCYTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT;

ACUTE HEART INFARCTION; ANALGESIA; ANTIPHOSPHOLIPID SYNDROME; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; DRUG INDUSTRY; GREECE; HUMAN; MALARIA; MUCOCUTANEOUS LYMPH NODE SYNDROME; POSTOPERATIVE PAIN; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RHEUMATIC FEVER; SOUTH AMERICA; THROMBOCYTE FUNCTION; THROMBOTIC THROMBOCYTOPENIC PURPURA; TRADITIONAL MEDICINE; UPPER GASTROINTESTINAL BLEEDING; VENOUS THROMBOEMBOLISM; VON WILLEBRAND DISEASE; BARK; BLEEDING; CARDIOVASCULAR DISEASES; CHEMICALLY INDUCED; DRUG DEVELOPMENT; FORECASTING; HEMATOLOGIC DISEASES; HISTORY; WILLOW;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIPYRETICS; ASPIRIN; CARDIOVASCULAR DISEASES; DRUG DISCOVERY; FORECASTING; HEMATOLOGIC DISEASES; HEMORRHAGE; HISTORY, 18TH CENTURY; HISTORY, 19TH CENTURY; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HISTORY, ANCIENT; PLANT BARK; PLATELET AGGREGATION INHIBITORS; SALIX;

EID: 85009959460     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.14520     Document Type: Review

References (87)

1. Aguilar, M. & Hart, R. (2005) Antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks. Cochrane Database of Systematic Reviews, 4, CD001925.
2. Aguilar, M.I., Hart, R. & Pearce, L.A. (2007) Oral anticoagulants versus antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no history of stroke or transient ischemic attacks. Cochrane Database of Systematic Reviews, 3, CD006186.
3. Algra, A.M. & Rothwell, P.M. (2012) Effects of regular aspirin on long-term cancer incidence and metastases: a systematic comparison of evidence from observational studies versus randomised trials. Lancet Oncology, 13, 518–527.
4. American Society of Anesthesiologists Task Force on Perioperative Blood Management. (2015) Practice guidelines for perioperative blood management: an updated report by the American Society of Anesthesiologists Task Force on Perioperative Blood Management. Anesthesiology, 122, 241–275.
5. Antiplatelet Trialists’ Collaboration. (1994a) Collaborative overview of randomised trials of antiplatelet therapy-I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ, 308, 81–106.
6. Antiplatelet Trialists’ Collaboration. (1994b) Collaborative overview of randomised trials of antiplatelet therapy-II: maintenance of vascular graft or arterial patency by antiplatelet therapy. BMJ, 308, 159–168.
7. Antiplatelet Trialists’ Collaboration. (1994c) Collaborative overview of randomised trials of antiplatelet therapy-III: reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients. BMJ, 308, 235–246.
8. Baharoglu, M.I., Cordonnier, C., Salman, R.A., de Gans, K., Koopman, M.M., Brand, A., Majoie, C.B., Beenen, L.F., Marquering, H.A., Vermeulen, M., Nederkoorn, P.J., de Haan, R.J. & Roos, Y.B. (2016) Platelet transfusion versus standard care after acute stroke due to spontaneous cerebral haemorrhage associated with antiplatelet therapy (PATCH): a randomised, open-label, phase 3 trial. Lancet, 387, 2605–2613.
9. Becattini, C., Agnelli, G., Schenone, A., Eichinger, S., Bucherini, E., Silingardi, M., Bianchi, M., Moia, M., Ageno, W., Vandelli, M.R., Grandone, E. & Prandoni, P. WARFASA Investigators. (2012) Aspirin for preventing the recurrence of venous thromboembolism. New England Journal of Medicine, 366, 1959–1967.
10. Bibbins-Domingo, K.; U.S. Preventive Services Task Force. (2016) Aspirin use for the primary prevention of cardiovascular disease and colorectal cancer: U.S. Preventive Services Task Force Recommendation Statement. Annals of Internal Medicine, 164, 836–845.
11. Bizzozero, G. (1882) Su di un nuovo elemento morfologico del sangue dei mammiferi e sulla sua importanza nella trombosi e nella coagulazione. Osservatore Gazetta delle Cliniche, 17, 785–787.
12. Born, G.V. (1962) Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature, 194, 927–929.
13. Brighton, T.A., Eikelboom, J.W., Mann, K., Mister, R., Gallus, A., Ockelford, P., Gibbs, H., Hague, W., Xavier, D., Diaz, R., Kirby, A. & Simes, J.; ASPIRE Investigators. (2012) Low-dose aspirin for preventing recurrent venous thromboembolism. New England Journal of Medicine, 367, 1979–1987.
14. Bryan, C.P. (1931) The Papyrus Ebers. Appleton, New York, NY.
15. Collier, H.O.J. & Shorley, P.G. (1970) Analgesic antipyretic drugs as antagonists of bradykinin. British Journal of Pharmacology, 15, 601–610.
16. Craven, L.L. (1950a) Acetylsalicylic acid, possible preventive of coronary thrombosis. Annals of Western Medicine and Surgery, 4, 95.
17. Craven, L.L. (1950b) Coronary artery thrombosis can be prevented. Journal of Insurance Medicine, 5, 47–48.
18. Craven, L.L. (1953) Experiences with aspirin (acetylsalicylic acid) in the nonspecific prophylaxis of coronary thrombosis. Mississippi Valley Medical Journal, 75, 38–44.
19. Craven, L.L. (1956) Prevention of coronary and cerebral thrombosis. Mississippi Valley Medical Journal, 78, 213–215.
20. Douthwaite, A.H. (1938) Some recent advances in medical diagnosis and treatment. British Medical Journal, 1, 1143–1146.
21. Douthwaite, A. & Lintott, G.A.M. (1938) Gastroscopic observations of the gastric mucosa after use of aspirin. Lancet, 2, 1222–1225.
22. Eichengrün, A. (1949) 50 Jahre Aspirin. Pharmazie, 4, 582–584.
23. Elwood, P.C., Cochrane, A.L., Burr, M.L., Sweetnam, P.M., Williams, G., Welsby, E., Hughes, S.J. & Renton, R. (1974) A randomized controlled trial of acetyl salicylic acid in the secondary prevention of mortality from myocardial infarction. British Medical Journal, 1, 436–440.
24. Ferraris, V.A., Saha, S.P., Oestreich, J.H., Song, H.K., Rosengart, T., Reece, T.B., Mazer, C.D., Bridges, C.R., Despotis, G.J., Jointer, K. & Clough, E.R. (2012) 2012 Update to the Society of Thoracic Surgeons guideline on use of antiplatelet drugs in patients having cardiac and noncardiac operations. Annals of Thoracic Surgery, 94, 1761–1781.
25. Flower, R. (2005) Obituary: Sir John Vane FRS. Nature Reviews Drug Discovery, 4, 10.
26. Gerhardt, C.H. (1853) Untersuchungen über die wasserfreien organischen Säuren. Justus Liebigs Annalen der Chemie, 87, 149–179.
27. Hamberg, M., Svensson, J. & Samuelsson, B. (1975) Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. Proceedings of the National Academy of Sciences of the United States of America, 72, 2994–2998.
28. Harrison, C.N., Bareford, D., Butt, N., Campbell, P., Conneally, E., Drummond, M., Erber, W., Everington, T., Green, A.R., Hall, G.W., Hunt, B.J., Ludlam, C.A., Murrin, R., Nelson-Piercy, C., Radia, D.H., Reilly, J.T., Van der Walt, J., Wilkins, B. & McMullin, M.F.; for the British Committee for Standards in Haematology. (2010) Guideline for investigation and management of adults and children presenting with a thrombocytosis. British Journal of Haematology, 149, 352–375.
29. Hearnshaw, S.A., Logan, R.F., Lowe, D., Travis, S.P., Murphy, M.F. & Palmer, K.R. (2011) Acute upper gastrointestinal bleeding in the UK: patient characteristics, diagnoses and outcomes in the 2007 UK audit. Gut, 60, 1327–1335.
30. Hemler, M., Lands, W.E. & Smith, W.L. (1976) Purification of the cyclooxygenase that forms prostaglandins. Demonstration of two forms of iron in the holoenzyme. Journal of Biological Chemistry, 251, 5575–5579.
31. ISIS-2 Collaborative Group. (1988) Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Lancet, 2, 349–360.
32. Jeffreys, D. (2004) Aspirin – The Story of a Wonder Drug. Bloomsbury, London.
33. Keeling, D., Mackie, I., Moore, G.W., Greer, I.A. & Greaves, M.; British Committee for Standards in Haematology. (2012) Guidelines on the investigation and management of antiphospholipid syndrome. British Journal of Haematology, 157, 47–58.
34. Kernan, W.N., Ovbiagele, B., Black, H.R., Bravata, D.M., Chimowitz, M.I., Ezekowitz, M.D., Fang, M.C., Fisher, M., Furie, K.L., Heck, D.V., Johnston, S.C., Kasner, S.E., Kittner, S.J., Mitchell, P.H., Rich, M.W., Richardson, D., Schwamm, L.H. & Wilson, J.A.; American Heart Association Stroke Council, Council on Cardiovascular and Stroke Nursing, Council on Clinical Cardiology, and Council on Peripheral Vascular Disease. (2014) Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke, 45, 2160–2236.
35. Kozek-Langenecker, S.A., Afshari, A., Albaladejo, P., Santullano, C.A., De Robertis, E., Filipescu, D.C., Fries, D., Görlinger, K., Haas, T., Imberger, G., Jacob, M., Lancé, M., Llau, J., Mallett, S., Meier, J., Rahe-Meyer, N., Samama, C.M., Smith, A., Solomon, C., Van der Linden, P., Wikkelsø, A.J., Wouters, P. & Wyffels, P. (2013) Management of severe perioperative bleeding: guidelines from the European Society of Anaesthesiology. European Journal of Anaesthesia, 30, 270–382.
36. Lancet Editorial. (1935) The use of aspirin and Sod. Sal. Lancet, 226, 619–620.
37. Landolfi, R., Marchioli, R., Kutti, J., Gisslinger, H., Tognoni, G., Patrono, C. & Barbui, T.; European Collaboration on Low-Dose Aspirin in Polycythemia Vera Investigators. (2004) Efficacy and safety of low-dose aspirin in polycythemia vera. New England Journal of Medicine, 350, 114–124.
38. Larocca, A., Cavallo, F., Bringhen, S., Di Raimondo, F., Falanga, A., Evangelista, A., Cavalli, M., Stanevsky, A., Corradini, P., Pezzatti, S., Patriarca, F., Cavo, M., Peccatori, J., Catalano, L., Carella, A.M., Cafro, A.M., Siniscalchi, A., Crippa, C., Petrucci, M.T., Yehuda, D.B., Beggiato, E., Di Toritto, T.C., Boccadoro, M., Nagler, A. & Palumbo, A. (2012) Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide. Blood, 119, 933–939.
39. Le Quellec, S., Bordet, J.C., Negrier, C. & Dargaud, Y. (2016) Comparison of current platelet functional tests for the assessment of aspirin and clopidogrel response. A review of the literature. Thrombosis and Haemostasis, 116, 638–650.
40. Leroux, H. (1830) Découvert de la salicine. Journal de Chimie Médicale, 6, 341.
41. Levine, S.R., Brey, R.L., Tilley, B.C., Thompson, J.L., Sacco, R.L., Sciacca, R.R., Murphy, A., Lu, Y., Costigan, T.M., Rhine, C., Levin, B., Triplett, D.A. & Mohr, J.P. (2004) Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke. JAMA, 291, 576–584.
42. Li, C., Hirsh, J., Xie, C., Johnston, M.A. & Eikelboom, J.W. (2012) Reversal of the anti-platelet effects of aspirin and clopidogrel. Journal of Thrombosis and Haemostasis, 10, 521–528.
43. Linnemann, Jr, C.C., Shea, L., Partin, J.C., Schubert, W.K. & Schiff, G.M. (1975) Reye's syndrome: epidemiologic and viral studies, 1963–1974. American Journal of Epidemiology, 101, 517–526.
44. Lovelock, C.E., Molyneux, A.J. & Rothwell, P.M.; Oxford Vascular Study. (2007) Change in incidence and aetiology of intracerebral haemorrhage in Oxfordshire, UK, between 1981 and 2006: a population-based study. Lancet Neurology, 6, 487–493.
45. Lyman, G.H., Bohlke, K., Khorana, A.A., Kuderer, N.M., Lee, A.Y., Arcelus, J.I., Balaban, E.P., Clarke, J.M., Flowers, C.R., Francis, C.W., Gates, L.E., Kakkar, A.K., Key, N.S., Levine, M.N., Liebman, H.A., Tempero, M.A., Wong, S.L., Somerfield, M.R. & Falanga, A.; for the American Society of Clinical Oncology. (2015) Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update 2014. Journal of Clinical Oncology, 33, 654–656.
46. MacLagan, T. (1876a) The treatment of acute rheumatism by salicin. Lancet, I, 342–343 & 383–384.
47. MacLagan, T. (1876b) The treatment of acute rheumatism by salicin. Lancet, I, 585.
48. MacLagan, T. (1876c) The willow as a remedy for acute rheumatism. Lancet, I, 910.
49. Makris, M., Van Veen, J.J., Tait, C.R., Mumford, A.D. & Laffan, M. (2013) Guideline on the management of bleeding in patients on antithrombotic agents. British Journal of Haematology, 160, 35–46.
50. Michelson, A.D., Cattaneo, M., Eikelboom, J.W., Gurbel, P., Kottke-Marchant, K., Kunicki, T.J., Pulcinelli, F.M., Cerletti, C. & Rao, A.K.; Platelet Physiology Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis; Working Group on Aspirin Resistance. (2005) Aspirin resistance: position paper of the Working Group on Aspirin Resistance. Journal of Thrombosis and Haemostasis, 3, 1309–1311.
51. Mortimer, E.A. (1962) Varicella with hypoglycaemia possibly due to salicylates. American Journal of Diseases in Children, 103, 583–590.
52. National Institute for Health and Care Excellence. (2008) Stroke and transient ischaemic attack in over 16s: diagnosis and initial management. NICE guideline CG68. Available online at: https://www.nice.org.uk/Guidance/cg68. (Accessed 27th December 2016).
53. National Institute for Health and Care Excellence. (2013) Myocardial infarction: cardiac rehabilitation and prevention of further cardiovascular disease. NICE guideline CG172. Available online at: https://www.nice.org.uk/Guidance/cg172. (Accessed 27th December 2016).
54. National Institute for Health and Care Excellence. (2014) Atrial fibrillation: management. NICE guideline CG180. Available online at: https://www.nice.org.uk/guidance/cg180. (Accessed 27th December 2016).
55. National Institute for Health and Care Excellence. (2015) Antiplatelet treatment. NICE clinical knowledge summary. Available online at: http://cks.nice.org.uk/antiplatelet-treatment. (Accessed 27th December 2016).
56. O'Brien, J.R. (1962) Platelet aggregation: part I. Some effects of the adenosine phosphates, thrombin, and cocaine upon platelet adhesiveness. Journal of Clinical Pathology, 15, 446–452.
57. O'Brien, J.R. (1963) Some effects of adrenaline and anti-adrenaline compounds on platelets in vitro and in vivo. Nature, 200, 763–764.
58. O'Gara, P.T., Kushner, F.G., Ascheim, D.D., Casey, Jr, D.E., Chung, M.K., de Lemos, J.A., Ettinger, S.M., Fang, J.C., Fesmire, F.M., Franklin, B.A., Granger, C.B., Krumholz, H.M., Linderbaum, J.A., Morrow, D.A., Newby, L.K., Ornato, J.P., Ou, N., Radford, M.J., Tamis-Holland, J.E., Tommaso, J.E., Tracy, C.M., Woo, Y.J. & Zhao, D.X.; CF/AHA Task Force. (2013) 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation, 127, 529–555.
59. Palumbo, A., Cavo, M., Bringhen, S., Zamagni, E., Romano, A., Patriarca, F., Rossi, D., Gentilini, F., Crippa, C., Galli, M., Nozzoli, C., Ria, R., Marasca, R., Montefusco, V., Baldini, L., Elice, F., Callea, V., Pulini, S., Carella, A.M., Zambello, R., Benevolo, G., Magarotto, V., Tacchetti, P., Pescosta, N., Cellini, C., Polloni, C., Evangelista, A., Caravita, T., Morabito, F., Offidani, M., Tosi, P. & Boccadoro, M. (2011) Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial. Journal of Clinical Oncology, 29, 986–993.
60. Patrono, C., Coller, B., Dalen, J.E., Fuster, V., Gent, M., Harker, L.A., Hirsh, J. & Roth, G. (1998) Platelet-active drugs: the relationships among dose, effectiveness, and side effects. Chest, 114, 470S–488S.
61. Patrono, C., Coller, B., FitzGerald, G.A., Hirsh, J. & Roth, G. (2004) Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest, 126, 234S–264S.
62. Peto, R. (1980) Aspirin after myocardial infarction. Lancet, I, 1172–1173.
63. Piper, P.J. & Vane, J.R. (1969) Release of additional factors in anaphylaxis and its antagonism by anti-inflammatory drugs. Nature, 223, 29–35.
64. Piria, R. (1838) Sur la composition de la Salicine et sur quelques-unes de ses reactions. Comptes Rendues de l'Académie des Sciences, Paris. 6, 338.
65. Poole, J.C. & French, J.E. (1961) Thrombosis. Journal of Atherosclerosis Research, 1, 251–282.
66. Pulmonary Embolism Prevention Trial Collaborative Group. (2000) Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: pulmonary embolism prevention (PEP) trial. Lancet, 355, 1295–1302.
67. Quick, A.J. (1966) Salicylates and bleeding: the aspirin tolerance test. American Journal of Medical Sciences, 252, 265–269.
68. Reilly, I.A. & FitzGerald, G.A. (1987) Inhibition of thromboxane formation in vivo and ex vivo: implications for therapy with platelet inhibitory drugs. Blood, 69, 180–186.
69. Rossaint, R., Bouillon, B., Cerny, V., Coats, T.J., Duranteau, J., Fernández-Mondéjar Filipescu, E.D., Hunt, B.J., Komadina, R., Nardi, G., Neugebauer, E.A., Ozier, Y., Riddez, L., Schultz, A., Vincent, J.L. & Spahn, D.R. (2016) The European guideline on management of major bleeding and coagulopathy following trauma: fourth edition. Critical Care, 20, 100.
70. Rothwell, P.M., Wilson, M., Elwin, C.E., Norrving, B., Algra, A., Warlow, C.P. & Meade, T.W. (2010) Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet, 376, 1741–1750.
71. Schindler, P.E. (1978) Aspirin Therapy. Walker and Co., New York, NY.
72. Schmidt, A. (1934) Die Industrielle Chemie in ihrer Bedeutung im Weltbild und Erinnerungen an ihren Aufbau. De Greuter, Berlin, 775 pp.
73. Schultze, M. (1865) Ein heizbarer Objecttisch und seine Verwendung bei Untersuchungen des Blutes. Archiv für Mikroscopische Anatomie, 1, 1–42.
74. Scully, M., Longair, I., Flynn, M., Berryman, J. & Machin, S.J. (2007) Cryosupernatant and solvent detergent fresh-frozen plasma (Octaplas) usage at a single centre in acute thrombotic thrombocytopenic purpura. Vox Sanguinis, 93, 154–158.
75. Scully, M., Hunt, B.J., Benjamin, S., Liesner, R., Rose, P., Peyvandi, F., Cheung, B. & Machin, S.J.; for the British Committee for Standards in Haematology. (2012) Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies. British Journal of Haematology, 158, 323–335.
76. Shanks, G.D. (2014) How World War 1 changed global attitudes to war and infectious diseases. Lancet, 384, 1699–1707.
77. Smith, T., Elwood, P., Keating, C., Rothwell, P., Detering, E., Freedman, A., Langley, R., Logan, R., Phillips, C. & DeCensi, A. (2014) The Aspirin Foundation Scientific Conference: the history, the present state and the future of aspirin prophylaxis. Ecancer, 8, 388.
78. Sneader, W. (2000) The discovery of aspirin: a reappraisal. BMJ, 321, 1591–1594.
79. Stone, E. (1763) An account of the succefs of the bark of the willow in the cure of agues. Philosophical Transactions, 53, 195–200.
80. The Canadian Cooperative Study Group. (1978) A randomized trial of aspirin and sulfinpyrazone in threatened stroke. New England Journal of Medicine, 299, 53–59.
81. The Dutch TIA Trial Study Group. (1991) A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischaemic attack or minor ischemic stroke. New England Journal of Medicine, 325, 1261–1266.
82. The SALT Collaborative Group. (1991) Swedish aspirin low-dose trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events. Lancet, 338, 1345–1349.
83. Thiele, T., Sumnig, A., Hron, G., Muller, C., Althaus, K., Schroeder, H.W. & Greinacher, A. (2012) Platelet transfusion for reversal of dual antiplatelet therapy in patients requiring urgent surgery: a pilot study. Journal of Thrombosis and Haemostasis, 10, 968–971.
84. Vane, J.R. (1971) Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature: New Biology, 231, 232–235.
85. Vilahur, G., Choi, B.G., Zafar, M.U., Viles-Gonzalez, J.F., Vorchheimer, D.A., Fuster, V. & Badimon, J.J. (2007) Normalization of platelet reactivity in clopidogrel-treated subjects. Journal of Thrombosis and Haemostasis, 5, 82–90.
86. Weiss, H.J. & Aledort, L.M. (1967) Impaired platelet-connective-tissue reaction in man after aspirin ingestion. Lancet, 2, 495–497.
87. Wood, J.N. (2015) From plant extract to molecular panacea: a commentary on Stone (1763) ‘An account of the success of the bark of the willow in the cure of the agues’. Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences, 370, pii:20140317.